Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of hereditary angioedema

An angioedema, genetic technology, applied in the field of treatment of hereditary angioedema, can solve problems such as high patient burden

Pending Publication Date: 2022-03-01
KALVISTA PHARMA
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, as injectables, these treatments all involve a high patient burden

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of hereditary angioedema
  • Treatment of hereditary angioedema
  • Treatment of hereditary angioedema

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] Example 1 - Preparation of Compounds of Formula A

[0155] A. 1-(4-Hydroxymethyl-benzyl)-1H-pyridin-2-one

[0156] 4-(Chloromethyl)benzyl alcohol (5.0 g, 31.93 mmol) was dissolved in acetone (150 mL). 2-Hydroxypyridine (3.64 g, 38.3 mmol) and potassium carbonate (13.24 g, 95.78 mmol) were added and the reaction mixture was stirred at 50 °C for 3 h, after which the solvent was removed in vacuo and the residue was dissolved in chloroform (100 mL) )middle. The solution was washed with water (30 mL), brine (30 mL) and dried (Na 2 SO 4 ) and evaporated in vacuo. The residue was purified by flash chromatography (silica), eluent 3% MeOH / 97% CHCl 3 , gave a white solid, which was identified as 1-(4-hydroxymethyl-benzyl)-1H-pyridin-2-one (5.30 g, 24.62 mmol, 77% yield).

[0157] [M+Na] + = 238

[0158] B. 1-(4-Chloromethyl-benzyl)-1H-pyridin-2-one

[0159] 1-(4-Hydroxymethyl-benzyl)-1H-pyridin-2-one (8.45 g, 39.3 mmol), dry DCM (80 mL) and triethylamine (7.66 ml, 55.0...

Embodiment 2

[0183] Example 2 - Preparation of Dosage Forms Comprising Compounds of Formula A

[0184] Blending and Rolling

[0185] Equipment: Freund Vector TFC Lab Micro Roller and Pelletizer (Roller and Pelletizer are separate entities). The device parameters are as follows:

[0186] parameter scope of use Screw speed(rpm) 10.0-20.0 Roll speed (rpm) 1.0-2.0 Roll force (kN) 0.50-12.00 Granulator screen size (mm) 1

[0187] method

[0188] Two tablet formulations (tablets A and B) were prepared at the 30 g blending scale according to the following procedure to produce tablets with the components in the amounts indicated below.

[0189]

[0190] For each of the tablets, a blend was prepared by passing the intragranular components through a 355 μm screen in a glass vessel using a Turbula blender at 34 rpm at a scale suitable for the roller compactor range. The blend was then passed through a roller press using the parameters described abo...

Embodiment 3

[0197] Example 3 - Comparison of Compounds of Formula A with C1 Inhibitors (C1-INH)

[0198] Purpose: To identify the biochemical and physiological properties of compounds of formula A that contribute to the control of optimal efficacy of the kallikrein kinin system in plasma. These properties were then compared to C1-INH (as a therapeutic benchmark for HAE).

[0199] method:

[0200] In vitro plasma kallikrein inhibitory activity was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori et al., Biochem. Pharmacol., 1992, 43, 1209; Stürzebecher et al. , Biol. Chem. Hoppe-Seyler, 1992, 373, 1025). Human plasma kallikrein (Protogen) was incubated at 25°C with the fluorogenic substrate H-DPro-Phe-Arg-AFC and various concentrations of test compounds. Residual enzyme activity (initial reaction rate) was determined by measuring the change in absorbance at 410 nm and determining the IC of the test compound 50 value.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the treatment of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatment of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor on demand to a patient in need thereof. Periodic (or continuous) treatment of HAE is also provided.

Description

[0001] The present invention relates to the treatment of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatment of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to patients in need as needed. Periodic (or continuous) treatment of HAE is also provided. Background technique [0002] Inhibitors of plasma kallikrein have various therapeutic applications, especially in the treatment of hereditary angioedema. [0003] Plasma kallikrein is a trypsin-like serine protease that releases kinins from kininogens (see K.D. Bhoola et al., "Kallikrein-Kinin Cascade", Encyclopedia of Respiratory Medicine , p483-493; J.W.Bryant et al., "Human plasma kallikrein-kinin system: physiological and biochemical parameters (human plasma kallikrein-kinin system: physiological and biochemical parameters)" Cardiovascular and haematological agents in medicinalchemistry, 7, p234 -250, 2009; K.D.Bhoola et al., Pharmacological Rev., ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/444A61P7/10A61P29/00A61P1/08A61P1/12A61P11/00A61P25/00
CPCA61K31/444A61P7/10A61P29/00A61P1/08A61P1/12A61P11/00A61P25/00A61P9/00A61K9/0053A61P17/00
Inventor 爱德华·保罗·费尼尔萨利·路易斯·马什安德烈亚斯·梅茨尔迈克尔·戴维·史密斯克里斯多夫·马丁·叶
Owner KALVISTA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com